PCSK9 and Alzheimer disease: The peripheral inhibition of PCSK9 by mAbs reduced, in AD mice, Aβ pathology in the prefrontal cortex and hippocampus areas critically involved in memory processing and prevented disease-related impairment in hippocampus-dependent memory formation, suggesting drug efficacy specifically for AD treatment [89].